Toxoplasmosis, caused by an intracellular protozoan parasite, Toxoplasma gondii, is widespread throughout the world. The disease is of major medical and veterinary importance, being a cause of congenital disease and abortion in humans and domestic animals. In addition, recently it has gained importance owing to toxoplasma encephalitis in AIDS patients. In the last few years, there has been considerable progress towards the development of a vaccine for toxoplasmosis, and a vaccine based on the live-attenuated S48 strain was developed for veterinary uses. However, this vaccine is expensive, causes side effects and has a short shelf life. Furthermore, this vaccine may revert to a pathogenic strain and, therefore, is not suitable for human use. Various experimental studies have shown that it may be possible to develop a vaccine against human toxoplasmosis. Recent progress in knowledge of the protective immune response generated by T. gondii and the current status of development of a vaccine for toxoplasmosis are highlighted.

Toxoplasma gondii SAG1, GRA1, and GRA7 recombinant antigens may be regarded as tools for the detection of T. gondii immunoglobulin G antibodies in persons with chronic and acute toxoplasmosis. GRA7 is more correlated with acute toxoplasmosis. A combination of these antigens will increase the sensitivity of enzymelinked immunosorbent assays.

No abstract

Toxoplasmosis, an infection caused by Toxoplasma (T.) gondii Apicomplexa protozoan, is widespread in humans and other animal species, having already been reported in many countries and different climates. In Pakistan, no data is available on this aspect among food animals. This study was undertaken to determine the seroprevalence of T. gondii infection in sheep and goats. A total of 200 serum samples from sheep and goats, were collected from urban area of Rahim Yar Khan (Punjab), Pakistan and tested for Toxoplasmosis with a commercial latex agglutination kit (Eiken Chemical Co., Ltd. Japan). The overall seroprevalence of Toxoplasmosis was 19%. Goats had a significantly higher (p < 0.01) prevalence (25.4%) as compared to the sheep (11.2%); and higher (p < 0.01) in the female (24%) than in the males (19%) for both species. In the present study the male (both in sheep and goat) are found less seropositive T. gondii (OR = 0.23; 99% C.I. = 0.01, 1.81) as compared to female sheep and goat. The prevalence was significantly higher (p < 0.01) in adult sheep than younger animals. Among both the sheep and goats the group from 1-1.5 years are highly seropositive (OR = 1.75; 99% C.I. = 0.47, 6.51) as compared to the group less than one year of age followed by the 2-2.5 years age group (OR = 1.63; 99% C.I. = 0.50, 5.74) whereas group with more than 3 years of age least seropositive.

The precise diagnosis of an acute and recent Toxoplasma infection in pregnant women and the newborn child is important before treatment. This study describes a new Toxoplasma gondii IgG avidity test based on a combination of recombinant GRA1, GRA7 and SAG1 antigens and shows that this test is useful for diagnostic purposes and may replace the lysed, whole-cell antigens. Although more sera need to be tested, the results obtained here suggest that the IgG avidity test performed with rec-antigens correlated more with the stage of a T. gondii infection than the IgG avidity results obtained with the lysed, whole-cell antigen test, the VIDAS Toxo IgG avidity (bioMérieux).